Basic Information
| LncRNA/CircRNA Name | MIAT |
| Synonyms | NA |
| Region | GRCh38_22:26646428-26676475 |
| Ensemble | ENSG00000225783 |
| Refseq | NR_003491 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | clear cell renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR, Luciferase assays |
| Sample | clear cell renal cell carcinoma tissues, cell lines(Caki-1, ACHN, 786-O, HK-2) |
| Expression Pattern | up-regulated |
| Function Description | MIAT was up-regulated in ccRCC tissues and cell lines. High MIAT expression correlated with worse clinicopathological features and shorter survival rate. Functional assays showed that knockdown of MIAT inhibited renal cancer cell proliferation and metastasis in vitro and in vivo. Luciferase and western blot assays further confirmed that miR-29c binds with MIAT. |
| Pubmed ID | 30041179 |
| Year | 2018 |
| Title | Upregulation of MIAT Regulates LOXL2 Expression by Competitively Binding MiR-29c in Clear Cell Renal Cell Carcinoma. |
External Links
| Links for MIAT | GenBank HGNC NONCODE |
| Links for clear cell renal cell carcinoma | OMIM COSMIC |